A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

February 15, 2027

Study Completion Date

May 15, 2028

Conditions

Pneumococcal InfectionsStreptococcal InfectionsBacterial Infections

Interventions

BIOLOGICAL

PCV13i

3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)

BIOLOGICAL

Prevnar 13

3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)